US 11,718,641 B2
Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
Guoqiang Wang, Belmont, MA (US); Yat Sun Or, Waltham, MA (US); Ruichao Shen, Belmont, MA (US); Jiang Long, Wayland, MA (US); Peng Dai, Auburndale, MA (US); Xuechao Xing, Wilmington, MA (US); and Jing He, Somerville, MA (US)
Assigned to Enanta Pharmaceuticals, Inc., Watertown, MA (US)
Filed by Enanta Pharmaceuticals, Inc., Watertown, MA (US)
Filed on Feb. 26, 2021, as Appl. No. 17/186,447.
Application 17/186,447 is a continuation of application No. 16/878,329, filed on May 19, 2020, granted, now 10,968,249.
Application 16/878,329 is a continuation of application No. 16/222,380, filed on Dec. 17, 2018, granted, now 10,696,713, issued on Jun. 30, 2020.
Application 16/222,380 is a continuation of application No. 14/951,989, filed on Nov. 25, 2015, granted, now 10,208,081, issued on Feb. 19, 2019.
Claims priority of provisional application 62/084,769, filed on Nov. 26, 2014.
Claims priority of provisional application 62/103,374, filed on Jan. 14, 2015.
Prior Publication US 2021/0261600 A1, Aug. 26, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07J 41/00 (2006.01); C07J 43/00 (2006.01); C07J 9/00 (2006.01); C07J 51/00 (2006.01)
CPC C07J 41/0066 (2013.01) [C07J 41/0055 (2013.01); C07J 41/0088 (2013.01); C07J 43/003 (2013.01); C07J 43/006 (2013.01); C07J 9/005 (2013.01); C07J 41/0094 (2013.01); C07J 51/00 (2013.01)] 5 Claims
 
1. A compound represented by Formula (VI-A) or (VI-B), or a pharmaceutically acceptable salt thereof:

OG Complex Work Unit Chemistry
wherein:
m is 0, 1, 2 or 3; and
R10 is selected from hydrogen, substituted or unsubstituted —C1-C8 alkyl, substituted or unsubstituted —C2-C8 alkenyl, substituted or unsubstituted —C2-C8 alkynyl, and substituted or unsubstituted —C3-C8 cycloalkyl.